Healthcare provider profile · identity verified

Michael N Mclaughlin, PA-C

Physician Assistant · NEW BEDFORD, MA · NPI 1568939213

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Lamotrigine	Lamotrigine	580	76
Clonazepam	Clonazepam	524	78
Quetiapine Fumarate	Quetiapine Fumarate	524	71
Alprazolam	Alprazolam	432	54
Bupropion Xl	Bupropion Hcl	427	59
Trazodone Hcl	Trazodone Hcl	403	62
Lorazepam	Lorazepam	369	53
Aripiprazole	Aripiprazole	336	47
Risperidone	Risperidone	276	37
Escitalopram Oxalate	Escitalopram Oxalate	269	43
Clonidine Hcl	Clonidine Hcl	259	37
Doxepin Hcl	Doxepin Hcl	248	40
Olanzapine	Olanzapine	234	28
Sertraline Hcl	Sertraline Hcl	233	32
Prazosin Hcl	Prazosin Hcl	232	23
Zolpidem Tartrate	Zolpidem Tartrate	224	37
Fluoxetine Hcl	Fluoxetine Hcl	219	29
Mirtazapine	Mirtazapine	213	33
Buspirone Hcl	Buspirone Hcl	206	35
Venlafaxine Hcl Er	Venlafaxine Hcl	203	27
Vraylar	Cariprazine Hcl	181	29
Citalopram Hbr	Citalopram Hydrobromide	170	27
Propranolol Hcl	Propranolol Hcl	150	30
Hydroxyzine Hcl	Hydroxyzine Hcl	145	29
Diazepam	Diazepam	141	20
Benztropine Mesylate	Benztropine Mesylate	140	21
Divalproex Sodium Er	Divalproex Sodium	137	16
Hydroxyzine Pamoate	Hydroxyzine Pamoate	129	18
Duloxetine Hcl	Duloxetine Hcl	125	20
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	121	17
Amitriptyline Hcl	Amitriptyline Hcl	101	21
Topiramate	Topiramate	101	14
Ramelteon	Ramelteon	95	15
Lithium Carbonate	Lithium Carbonate	94	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	89	suppressed
Gabapentin	Gabapentin	82	12
Lurasidone Hcl	Lurasidone Hcl	81	13
Clozapine	Clozapine	79	suppressed
Divalproex Sodium	Divalproex Sodium	76	13
Paroxetine Hcl	Paroxetine Hcl	70	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	60	12
Perphenazine	Perphenazine	60	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	58	12
Bupropion Hcl Sr	Bupropion Hcl	48	15
Ziprasidone Hcl	Ziprasidone Hcl	47	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	45	suppressed
Paliperidone Er	Paliperidone	44	suppressed
Haloperidol Decanoate	Haloperidol Decanoate	37	suppressed
Oxcarbazepine	Oxcarbazepine	36	suppressed
Vyvanse	Lisdexamfetamine Dimesylate	36	suppressed
Rexulti	Brexpiprazole	35	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	34	suppressed
Bupropion Hcl	Bupropion Hcl	32	suppressed
Haloperidol	Haloperidol	32	suppressed
Trintellix	Vortioxetine Hydrobromide	32	suppressed
Lithium Carbonate Er	Lithium Carbonate	31	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	29	suppressed
Guanfacine Hcl Er	Guanfacine Hcl	29	suppressed
Varenicline Tartrate	Varenicline Tartrate	29	suppressed
Amantadine	Amantadine Hcl	25	suppressed
Clomipramine Hcl	Clomipramine Hcl	25	suppressed
Carbamazepine	Carbamazepine	24	suppressed
Carbamazepine Er	Carbamazepine	24	suppressed
Methylphenidate Er	Methylphenidate Hcl	24	suppressed
Temazepam	Temazepam	24	suppressed
Naltrexone Hcl	Naltrexone Hcl	23	suppressed
Baclofen	Baclofen	22	suppressed
Simvastatin	Simvastatin	22	suppressed
Omeprazole	Omeprazole	20	suppressed
Qelbree	Viloxazine Hcl	17	suppressed
Invega Sustenna	Paliperidone Palmitate	16	suppressed
Ropinirole Hcl	Ropinirole Hcl	15	suppressed
Atenolol	Atenolol	14	suppressed
Chlordiazepoxide-Amitriptyline	Amitriptyline/Chlordiazepoxide	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Memantine Hcl	Memantine Hcl	13	suppressed
Modafinil	Modafinil	13	suppressed
Belsomra	Suvorexant	12	suppressed
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	12	suppressed
Chlorpromazine Hcl	Chlorpromazine Hcl	12	suppressed
Cyproheptadine Hcl	Cyproheptadine Hcl	12	suppressed
Topamax	Topiramate	12	suppressed
Loxapine	Loxapine Succinate	11	suppressed
Wellbutrin Xl	Bupropion Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error